Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-ComersGlobeNewsWire • 06/03/22
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022GlobeNewsWire • 05/27/22
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual MeetingGlobeNewsWire • 04/28/22
Immutep's Efti in Combination with MSD's Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer PatientsGlobeNewsWire • 03/30/22
Immutep Announces Publication of TACTI-002 Abstract at ESMO's European Lung Cancer Congress 2022GlobeNewsWire • 03/24/22
Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure PlaySeeking Alpha • 03/21/22
Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO's Breast Cancer Congress 2022GlobeNewsWire • 03/18/22
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525GlobeNewsWire • 03/18/22
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast CancerGlobeNewsWire • 03/10/22
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO's European Lung Cancer Congress 2022GlobeNewsWire • 02/18/22
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway InhibitorGlobeNewsWire • 02/11/22
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003GlobeNewsWire • 12/02/21
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod AlphaGlobeNewsWire • 11/19/21
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway InhibitorGlobeNewsWire • 11/15/21
Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod AlphaGlobeNewsWire • 11/15/21
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast DetailsGlobeNewsWire • 11/09/21
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy AgentGlobeNewsWire • 11/02/21